Jacobs Levy Equity Management, Inc Biocryst Pharmaceuticals Inc Transaction History
Jacobs Levy Equity Management, Inc
- $23.9 Billion
- Q3 2025
A detailed history of Jacobs Levy Equity Management, Inc transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, Jacobs Levy Equity Management, Inc holds 370,463 shares of BCRX stock, worth $2.62 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
370,463
Previous 381,480
2.89%
Holding current value
$2.62 Million
Previous $3.42 Million
17.76%
% of portfolio
0.01%
Previous 0.01%
Shares
18 transactions
Others Institutions Holding BCRX
# of Institutions
310Shares Held
200MCall Options Held
640KPut Options Held
507K-
Vanguard Group Inc Valley Forge, PA21.8MShares$154 Million0.0% of portfolio
-
Black Rock Inc. New York, NY20MShares$141 Million0.0% of portfolio
-
Deerfield Management Company, L.P. (Series C) New York, NY12.2MShares$86.2 Million1.72% of portfolio
-
State Street Corp Boston, MA9.81MShares$69.4 Million0.0% of portfolio
-
Kynam Capital Management, LP Princeton, NJ9.39MShares$66.5 Million6.02% of portfolio
About BIOCRYST PHARMACEUTICALS INC
- Ticker BCRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 185,944,992
- Market Cap $1.32B
- Description
- BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...